LABU News and Press, Direxion Daily S&P Biotech Bull 3X Shares From 10/02/22

Summary Leveraged ETFs behavior is neither intuitive nor predictable. Below is a dashboard with 22 of them, including SPUU. LABD is the worst of the list. Focus on SPUU: drift history and comparison with UPRO. The Direxion Daily S&P 500 Bull 2X Shares ETF ( ...

Summary Leveraged ETFs have a non-linear behavior. Biotechnology ETFs LABU and LABD show very large drifts. Lessons of SPXS history. The Direxion Daily S&P 500 Bear 3X Shares ETF ( SPXS ) is one of the most popular instruments to short the broad market for tr...

Summary TAMS for Non-Alcoholic Steatohepatitis NASH after topline PH2a results and what it could mean to Cytodyn long term investors. Wall Street modeling of non-revenue generating biotechs. Headwinds and risks involved. Overview CytoDyn Inc. (CYDY) is a Vanc...

Summary Toripalimab approval will be decided for Coherus at the end of December. Cimerli approval has pushed up the stock. However, the tori PDUFA is the major catalytic event here. It is interesting to see that despite its foray into original R&D through a Chine...

Alnylam is rapidly becoming the leader in ATTR through its successful therapy, patisiran. Intellia has presented data showing even deeper reductions in TTR. Though early Intellia has the potential to show better clinical outcomes in patients with ATTR. For years, patient...

Atara has two possible regulatory approvals for tab-cel for PTLD; European approval expected Q4 of 2022 and BLA filing for U.S. territory to be updated in next quarter earnings call. Two data readouts of ATA188 for treatment of patients with progressive multiple sclerosis; Phase 1 MRI...

ImmunoGen announced that it will receive the FDA decision for mirvetuximab on November 28th. The deal with Oxford BioTechnologies will support further growth. ImmunoGen remains robust from a financial point of view. Two weeks ago, the leading biotech company ImmunoGen, I...

Results for both studies from the DISSOLVE phase 3 program, using SEL-212 for the treatment of patients with chronic refractory gout, are expected in Q1 of 2023. Potential to restore immune tolerance and target underlying cause of patients with primary biliary cirrhosis with use of Im...

During July, LABU traded in a narrow range. In August, its uptrend has resumed. We expect that LABU’s uptrend has a long way to go. A block of LABU trades started on July 21 has done extremely well so far. A paper trade done on SPXL is shown for comparison. In...

Gainers: Direxion Daily S&P Biotech Bull 3x Shares ETF ( LABU ) +44% . Axs 2X Innovation ETF ( TARK ) +22% . ProShares Trust II - ProShares UltraPro 3x Short Crude Oil ETF ( OILD ) +22% . Bank of Montreal Microsectors Travel 3X Inverse ( FLYU ...